Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $412.45, moving -0.49% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.12% for the day. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.

Shares of the drugmaker witnessed a loss of 0.97% over the previous month, trailing the performance of the Medical sector with its gain of 2.49% and the S&P 500's gain of 2.06%.

The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $4.07, reflecting a 33.44% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $2.55 billion, up 7.34% from the year-ago period.

VRTX's full-year Zacks Consensus Estimates are calling for earnings of $16.79 per share and revenue of $10.69 billion. These results would represent year-over-year changes of +10.24% and +8.27%, respectively.

Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.19% lower. Right now, Vertex Pharmaceuticals possesses a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Vertex Pharmaceuticals has a Forward P/E ratio of 24.68 right now. This valuation marks a premium compared to its industry's average Forward P/E of 23.47.

We can also see that VRTX currently has a PEG ratio of 2.01. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.63 at the close of the market yesterday.